IGC-510

IGC-510 is an investigational cannabinoid-based drug candidate from IGC Pharma focused on speech disorders and Tourette syndrome. Public disclosures describe it as a proprietary method or formulation using cannabinoids, initially described as cannabidiol for treating stammering and symptoms of Tourette syndrome, with later company disclosures broadening the concept to THC and or CBD microdose-based treatment for stammering, stuttering, and Tourette syndrome. The intended pharmacology appears to center on modulation of the endocannabinoid system, but the exact active composition, final product definition, and target profile have not been fully disclosed in public technical detail, and there is no evidence of regulatory approval or marketed status.